Tarsus Pharmaceuticals is a biopharmaceutical company dedicated to creating new categories in eye care and beyond. The company is driven by a deep commitment to serving patient needs and changing lives through revolutionary treatments.
Its first and only FDA-approved product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, targets the root cause of Demodex blepharitis, a highly prevalent and damaging eyelid disease. Tarsus is advancing a robust pipeline designed to address significant unmet patient needs in areas such as ocular rosacea and Lyme disease prevention.
The company's scientific approach focuses on treating the underlying cause of disease rather than just symptoms. This unconventional mindset, combined with a culture of teamwork, empowerment, and commitment, defines Tarsus's mission to deliver innovative therapies.